Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA-230 escalating single-dose safety, pharmacokinetic, and endotoxemia challenge study
NL-OMON40791Phase 1Active, not recruiting
- Sponsor
- Exponential Biotherapies, Inc.
- Start
- Jan 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Systemic Inflammatory Response Syndrome (SIRS), sepsis and acute kidney failure (AKF) comparing EA-230 with Placebo (2 arms). Primary endpoints: Safety and tolerability of EA-230 and TNF-alpha inflammatory response AUC during endotoxemia. Started Jan 2015; status: active, not recruiting.
02
Drugs
EA-230
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)sepsisacute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON40791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40791.